Conjugation of Cetuximab – Puromycin and Its Target-Specific Effect on Triple Negative Breast Cancer Cell Lines

Cancer is life-threatening disease and being global health problems. Chemotherapy is one of the most used therapy for cancer since many years ago. Chemotherapy is also toxic for normal cell, not specific to the target cells. Consequently, chemotherapy has various side effects. Monoclonal antibody (MAb) has been developed for specific therapy which only has killing effect in cancer cells, but the survival rate of most MAbs around 20%. Therefore, in clinical practice, MAbs administration should combine with chemotherapeutic agents. For effectiveness of therapy and to minimalize adverse effects, anticancer agent with selective cytotoxic effect on target cells is needed, the immunotoxin. Objective: This study introduces a novel approach to conjugate monoclonal antibody (Cetuximab) and toxin (Puromycin), in order to selectively inhibit proliferation of triple negative breast cancer (TNBC) and to enhance the efficacy of MAb in target cells killing. Methods: Cetuximab was conjugated with Puromycin using a linker, i.e SATP (Succinimidyl-acetylthiopropionate) and tested on triple negative breast cancer cell lines (MDA-MB-231) which expressed EGFR (epidermal growth factor receptor). Cetuximab is MAb which targets EGFR. MCF-7 was used as control cells since it has low or no EGFR expression. Cell counting were conducted as viability assay at 24 hours, 48 hours, and 72 hours after treatment. Results: The results showed significant reduction of live cells number in Conjugate 20 µg/mL cultured in MDA-MB-231 compared to MCF-7 after 24 hours, 48 hours, and 72 hours incubation. In all time period of incubation, significant reduction of MDA-MB-231 live cells number was also observed in Conjugate 20 µg/mL compared to Cetuximab 20 µg/mL. Conclusion: Synthesized conjugate showed its target-specific effect in TNBC and improved the efficacy of Cetuximab on TNBC. In the future, this conjugate can be a potential anticancer therapy in treating triple-negative breast cancer.

[1]  J. Grandis,et al.  Disruption of the HER3-PI3K-mTOR oncogenic signaling axis and PD-1 blockade as a multimodal precision immunotherapy in head and neck cancer , 2021, Nature Communications.

[2]  Jung,et al.  p53-Dependent Apoptotic Effect of Puromycin via Binding of Ribosomal Protein L5 and L11 to MDM2 and Its Combination Effect with RITA or Doxorubicin , 2019, Cancers.

[3]  V. Schirrmacher.  From chemotherapy to biological therapy: A review of novel concepts to reduce the side effects of systemic cancer treatment (Review) , 2018, International journal of oncology.

[4]  Yong-Sung Kim,et al.  Critical issues in the development of immunotoxins for anticancer therapy. , 2019, Journal of pharmaceutical sciences.

[5]  Sung-Bae Kim,et al.  How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategies , 2018, ESMO Open.

[6]  A. Spira,et al.  Product review on the Anti-PD-L1 antibody atezolizumab , 2018, Human vaccines & immunotherapeutics.

[7]  J. Balko,et al.  Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease , 2016, Nature Reviews Clinical Oncology.

[8]  M. Agarwal.  Is cancer chemotherapy dying? , 2016, Asian journal of transfusion science.

[9]  H. Rastegar,et al.  Preparation of Immunotoxin Herceptin-Botulinum and Killing Effects on Two Breast Cancer Cell Lines. , 2015, Asian Pacific journal of cancer prevention : APJCP.

[10]  D. Suckau,et al.  Correct primary structure assessment and extensive glyco-profiling of cetuximab by a combination of intact, middle-up, middle-down and bottom-up ESI and MALDI mass spectrometry techniques , 2013, mAbs.

[11]  Sung-Hoon Kim,et al.  Melatonin Suppresses the Expression of 45S Preribosomal RNA and Upstream Binding Factor and Enhances the Antitumor Activity of Puromycin in MDA-MB-231 Breast Cancer Cells , 2013, Evidence-based complementary and alternative medicine : eCAM.

[12]  S. Ethier,et al.  EGFR/Met association regulates EGFR TKI resistance in breast cancer , 2010, Journal of molecular signaling.

[13]  T. Sørlie,et al.  Triple‐negative breast cancer: Present challenges and new perspectives , 2010, Molecular oncology.

[14]  Yung-Hyun Choi,et al.  Gefitinib induces apoptosis and decreases telomerase activity in MDA-MB-231 human breast cancer cells , 2009, Archives of pharmacal research.

[15]  D. Drotar,et al.  Potential chemotherapy side effects: What do oncologists tell parents? , 2009, Pediatric blood & cancer.

[16]  G. Aruna.  Immunotoxins: A Review of Their Use in Cancer Treatment , 2006, Journal of stem cells & regenerative medicine.

[17]  Y. Luqmani.  Mechanisms of Drug Resistance in Cancer Chemotherapy , 2005, Medical Principles and Practice.

[18]  P. Jeffrey,et al.  Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. , 2005, Cancer cell.

[19]  R. Roberts,et al.  A general approach to detect protein expression in vivo using fluorescent puromycin conjugates. , 2004, Chemistry & biology.

[20]  R. Radinsky,et al.  Cancer Therapeutics: Understanding the Mechanism of Action , 2004, Toxicologic pathology.

[21]  H. Arnqvist,et al.  Inhibition of puromycin-induced apoptosis in breast cancer cells by IGF-I occurs simultaneously with increased protein synthesis. , 2004, Neoplasma.

[22]  G. Riethmüller,et al.  Monoclonal antibodies in cancer therapy , 2004, Springer Seminars in Immunopathology.

[23]  M. Perry,et al.  Classical Chemotherapy: Mechanisms, Toxicities and the Therapeutc Window , 2003, Cancer biology & therapy.

[24]  E. Vitetta,et al.  Chemical construction of immunotoxins. , 2000, Methods in molecular medicine.

[25]  G. Schultz,et al.  Characterization of epidermal growth factor receptor and action on human breast cancer cells in culture. , 1984, Cancer research.

[26]  D. Nathans.  INHIBITION OF PROTEIN SYNTHESIS BY PUROMYCIN. , 1964, Federation proceedings.

[27]  S. Parlee,et al.  This Work Is Licensed under a Creative Commons Attribution-noncommercial 4.0 International License , 2022 .